UnitedHealth faces July 16 earnings test with 71% beat probability

UnitedHealth Group Inc. heads into its July 16 earnings report with the strongest setup in managed care, carrying a 71% probability of beating Q2 consensus, according to prediction market data.

"The repricing thesis showed up once in Q1 and is set up to repeat next Thursday," Joel South, an analyst covering large-cap healthcare at 24/7 Wall St., said.

UnitedHealth delivered adjusted EPS of $7.23 in Q1 2026 versus a $6.60 consensus estimate, a 9.55% beat, while its medical care ratio improved 90 basis points to 83.9%. Operating cash flow jumped to $8.9 billion, up 63% year over year. Management raised full-year 2026 adjusted EPS guidance to greater than $18.25, up from the prior above-$17.75 mark.

The options market is pricing a 6.1% share move on July 16, according to Bloomberg data. The stock has exceeded the implied move in four of the past eight earnings announcements, including a 10.5% swing on April 21 versus a 5.4% implied move. Shares last traded around $430.72 on July 9, up 28% year to date and 42% over the past 12 months, recovering from a seven-year low of $234.60 in August 2025.

Analysts are overwhelmingly bullish, with 23 buy or strong-buy ratings against a single sell. The consensus price target stands at $418.04, implying a forward P/E of roughly 23 times. The Zacks consensus estimate calls for Q2 EPS of $4.84, an 18.6% increase from the prior-year quarter, on revenue of $110.05 billion.

UnitedHealth's competitive positioning has widened against peers. Humana is guiding FY 2026 adjusted EPS to at least $9.00, down 47% from $17.14 in FY 2025, driven by Star Ratings damage UnitedHealth does not carry. Elevance Health posted a benefit expense ratio of 93.5% in Q4 2025, swinging its Health Benefits segment to a loss. UnitedHealth's 83.9% medical cost ratio places it in a different tier, and its $388.9 billion market cap reflects the scale advantage.

The company plans roughly $8.0 billion in dividends and $2.5 billion in buybacks in 2026, with a $2 billion buyback tranche completed by the end of Q2. The annual dividend of $8.84 per share yields 2.15%.

The Q1 beat produced a 6.96% same-day gain and a 10.54% 30-day return, outperforming both the S&P 500 and the Nasdaq 100. A similar outcome on July 16 would reinforce the repricing narrative that has driven the stock's 57% rally since late March. Investors will watch for updated medical cost trends and any changes to the full-year guidance range.

This article is for informational purposes only and does not constitute investment advice.